Questions & explanations
1. What is the IASP 2017 definition of nociplastic pain?
Nociplastic pain is pain that arises from altered nociception (the process of sensing pain) without clear evidence of actual or threatened tissue damage causing the activation of peripheral nociceptors (pain-sensing nerve endings) or disease or damage of the somatosensory system (the part of the nervous system that processes sensory information). The IASP (International Association for the Study of Pain) criteria require that the pain is present for at least 3 months, is regional (not localized to a single nerve territory), and is not better explained by another pain condition. Key features include hypersensitivity to stimuli (allodynia, where normally non-painful touch causes pain, and hyperalgesia, increased pain from a normally painful stimulus) and psychological factors. The diagnosis is made after excluding other causes like inflammatory or neuropathic pain. These criteria help identify fibromyalgia and related conditions.
2. Compare nociplastic pain with neuropathic pain: give an example of each.
Nociplastic pain arises from altered central nervous system processing without clear nerve damage, like in fibromyalgia where pain is widespread and accompanied by fatigue. Neuropathic pain results from a lesion or disease of the somatosensory nervous system, such as in diabetic neuropathy where pain is burning, shooting, and follows a nerve distribution. A key difference: neuropathic pain often has a nerve injury cause (e.g., trauma, diabetes), while nociplastic pain does not. Also, neuropathic pain may show sensory loss in the affected area, whereas nociplastic pain typically shows hypersensitivity. Both can have allodynia, but the underlying mechanism differs. For example, a patient with shingles (herpes zoster) has neuropathic pain, while a patient with fibromyalgia has nociplastic pain.
3. How do you apply the IASP 2017 criteria to diagnose nociplastic pain in a patient with widespread pain?
First, confirm the pain has been present for at least 3 months and is widespread, meaning it affects multiple body regions (e.g., both sides of the body, above and below the waist). Next, rule out other causes like inflammation (e.g., arthritis) or nerve damage (e.g., diabetic neuropathy) through history, exam, and tests. Then, assess for hypersensitivity signs: ask if light touch, pressure, or temperature changes cause pain (allodynia) or if pain is stronger than expected (hyperalgesia). Also, look for associated symptoms like fatigue, sleep problems, or mood issues. If the patient meets these criteria and no other condition explains the pain, you can classify it as nociplastic pain. For example, a patient with chronic widespread pain, tender points, and no lab abnormalities fits.
4. Compare resting-state fMRI findings in fibromyalgia with those in chronic back pain.
Both conditions show altered functional connectivity, but patterns differ. In fibromyalgia, there is widespread increased connectivity between the default mode network (DMN) and pain regions (insula, anterior cingulate), and decreased connectivity in the descending pain modulatory system (e.g., periaqueductal gray). In chronic back pain, changes are more localized to sensorimotor networks and the DMN shows decreased connectivity with the insula. Also, fibromyalgia often involves more emotional and cognitive regions, reflecting its systemic nature. Both show disrupted salience network, but fibromyalgia has more pronounced hyperconnectivity. These differences suggest distinct mechanisms: central sensitization in fibromyalgia versus maladaptive plasticity in back pain.
5. What are functional connectivity and resting-state fMRI abnormalities in fibromyalgia?
Functional connectivity refers to how different brain regions communicate with each other. Resting-state fMRI (functional magnetic resonance imaging) measures brain activity when a person is awake but not doing a task. In fibromyalgia, studies show abnormal connectivity in several networks. For example, the default mode network (DMN), which is active during rest and self-reflection, shows increased connectivity with pain-processing regions like the insula and anterior cingulate cortex. This may explain why patients feel pain even without external stimuli. Also, the salience network, which detects important stimuli, is hyperconnected, making the brain overreact to pain signals. These changes contribute to chronic pain and other symptoms like fatigue.
6. Explain the conditioned pain modulation (CPM) protocol and what an impaired result means in fibromyalgia.
CPM protocol: First, measure a baseline pain response to a test stimulus, like heat pain on the forearm (test stimulus). Then, apply a conditioning stimulus elsewhere, such as immersing the opposite hand in cold water (about 10°C) for 1 minute (this is painful). Immediately after, measure the test stimulus again. Normally, the conditioning stimulus reduces the pain from the test stimulus (pain inhibits pain). In fibromyalgia, this reduction is often smaller or absent, meaning impaired CPM. This indicates that the brain's descending pain inhibitory pathways (which normally block pain signals) are not working well. Impaired CPM is a hallmark of central sensitization and helps explain why fibromyalgia patients have chronic widespread pain.
7. Compare HRV findings in fibromyalgia with those in chronic fatigue syndrome.
Both conditions show reduced HRV and autonomic dysfunction, but patterns may differ. In fibromyalgia, there is often a more pronounced sympathetic overactivity and reduced parasympathetic tone, especially during sleep. In chronic fatigue syndrome (CFS), some studies show similar findings, but others report a blunted sympathetic response to stress. Both have low HRV overall. However, fibromyalgia patients may have more pain-related autonomic changes, while CFS patients may have more orthostatic intolerance (dizziness on standing). Overlap is common because many patients have both conditions. Treatment approaches like graded exercise and stress management benefit both, but specific autonomic testing can guide tailored interventions.
8. What is heart rate variability (HRV) and how is it measured?
Heart rate variability (HRV) is the variation in time between consecutive heartbeats. It reflects the balance between the sympathetic (fight-or-flight) and parasympathetic (rest-and-digest) branches of the autonomic nervous system. Higher HRV generally indicates good autonomic flexibility and health. HRV is measured using an electrocardiogram (ECG) or a wearable heart rate monitor. The most common measure is the standard deviation of normal-to-normal intervals (SDNN). Another is the root mean square of successive differences (RMSSD), which reflects parasympathetic activity. Measurements are taken over short periods (e.g., 5 minutes) or 24 hours. Low HRV is linked to stress, illness, and chronic pain conditions like fibromyalgia.
9. What are gray matter volume reductions in fibromyalgia?
Gray matter is the part of the brain containing nerve cell bodies, involved in processing information. In fibromyalgia, brain imaging studies (like MRI) show that certain brain regions have less gray matter volume compared to healthy people. These regions include the anterior cingulate cortex (involved in pain perception), the insula (body awareness), the prefrontal cortex (decision-making), and the hippocampus (memory). The reductions are small but significant. They are thought to result from chronic pain and stress, which can shrink brain cells over time. However, these changes are not specific to fibromyalgia and can be seen in other chronic pain conditions. They may contribute to cognitive problems like poor concentration.
10. What are quantitative sensory testing (QST) and conditioned pain modulation (CPM)?
Quantitative sensory testing (QST) is a set of non-invasive tests that measure how your nervous system responds to different sensory stimuli like touch, pressure, heat, cold, and vibration. It helps detect abnormalities in pain perception, such as allodynia (pain from normally non-painful touch) or hyperalgesia (increased pain from a normally painful stimulus). Conditioned pain modulation (CPM) is a test of the brain's ability to reduce pain using another painful stimulus (like putting a hand in cold water). It assesses the 'pain inhibits pain' mechanism. In fibromyalgia, QST often shows heightened sensitivity, and CPM is often impaired, meaning the brain does not dampen pain well. These tools help understand pain processing.
11. How is QST performed to assess pain sensitivity in a fibromyalgia patient?
QST involves applying controlled stimuli to the skin. For example, use a device called an algometer to apply increasing pressure to a point (like the thumbnail) until the patient says it becomes painful (pressure pain threshold). Also, apply a heat probe that slowly increases temperature to measure heat pain threshold. Cold pain threshold is tested with a cold probe. To test allodynia, brush the skin lightly with a cotton swab; if it hurts, that's dynamic allodynia. For hyperalgesia, use a pinprick device. The patient rates pain intensity on a 0-10 scale. In fibromyalgia, thresholds are often lower (pain at weaker stimuli) and ratings higher. Results are compared to healthy controls to identify abnormal sensitivity.
12. Why is it important to distinguish nociplastic pain from other pain types for treatment?
Different pain types respond to different treatments. Nociplastic pain often improves with centrally acting drugs like tricyclic antidepressants (e.g., amitriptyline), gabapentinoids (e.g., pregabalin), and non-drug approaches like exercise and cognitive behavioral therapy. Neuropathic pain may respond to similar drugs but also to topical lidocaine or nerve blocks. Inflammatory pain (e.g., arthritis) responds to anti-inflammatory drugs. Using the wrong treatment can lead to poor outcomes. For example, opioids are less effective for nociplastic pain and risky. Correct classification guides therapy, avoids unnecessary tests, and helps set realistic expectations. It also aids research into specific mechanisms.